Taking people in ItalyNo phase
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
Key facts
- Who runs it
- AbbVie
- Where
- Bari, Cona, and Rome, ItalySee the 3 sitesAlso in 17 other countries, 113 sites
- Trial code
- Status
- Recruiting
- People taking part
- 2,795 people, planned
- Started
- 2 Sept 2025
- Expected to end
- Aug 2027
- Type of study
- Observational, 3 groups
- Record updated
- 13 February 2026
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
- Participants Ability to understand study questionnaires, with caregiver support as required for adolescents
Who cannot take part
- Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
- Unable or unwilling to comply with study requirements and PRO collection
Where in Italy
Also in 17 other countries, 113 sites
- A.O.U. Consorziale Policlinico di Bari /ID# 276857Bari, ItalyContact: Beth RycroftTaking people
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S.Anna /ID# 276986Cona, ItalyContact: Beth RycroftTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 277745Rome, ItalyContact: Beth RycroftTaking people
About the trial
What the trial wants to find out
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.
The 3 groups in the trial
- Participants with Vitiligo
Participants with vitiligo will undergo a single-visit data collection per routine clinical practice
- Participants with Alopecia Areata
Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice
- Participants with Hidradenitis Suppurativa
Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)
- Record updated
- 13 February 2026